newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra
Business

Stock market up

Stock markets rose on Monday amid choppy trade, with the S&P BSE Sensex index adding nearly 250 points in morning. The broader NSE Nifty benchmark climbed to as much as 11,233.85, up 59.1 points from its earlier close. Gains in banking and financial services stocks countered losses in pharma and energy shares. 

Meanwhile, equities in other Asian markets edged higher after data showed the US unemployment rate dropped to the lowest in almost 50 years, easing concerns of a slowdown in the world’s largest economy. MSCI’s broadest index of Asia-Pacific shares outside Japan rose 0.25 per cent and Japan’s Nikkei stock index climbed 0.29 per cent. 

Shares of BPCL fell over 3 per cent on Monday after the government repealed the legislation that had nationalised the company. On the BSE, the stock declined 3.53 per cent to Rs 497. The shares of the PSU fell 3.21 per cent to Rs 499 on the NSE. Ahead of a proposed move to fully privatise state-owned fuel retailer, the government has repealed the legislation that had nationalised the company, doing away with the need to seek Parliament nod before selling it off to private firms.

Drug firm Indoco Remedies on Monday said it has received approval from the US health regulator for Rasagiline tablets, used for treatment of Parkinson’s disease. The company has received last nod for its abbreviated new drug application (ANDA) for Rasagiline tablets in the strengths of 0.5 mg and 1 mg from the United States Food and Drug Administration (USFDA), Indoco Remedies said in a regulatory filing.

Related posts

EET Fuels secures further investor confidence in strategic decarbonisation ambition

Newsmantra

Mahindra launches the Scorpio-N Carbon to celebrate 200,000 sales milestone of the ‘Big Daddy of SUVs’ 

Newsmantra

Publicis India’s latest campaign for HDFC Mutual Fund targets first-time investors 

Newsmantra

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More